Fluidigm-Singapore completes final milestone toward full manufacturing operations

Off-shore fab positions Fluidigm to move rapidly into the real-time qPCR market


Fluidigm Corporation has announced that its Singapore-based manufacturing facility has ramped up to full process R&D and manufacturing operations, less than a year after opening its doors. The rapid startup boosts the Company's entry into the billion dollar real-time qPCR market, enabling production of BioMark(TM) dynamic arrays to supply high-end users. According to the company, these unique biochips increase qPCR efficiency by orders of magnitude and may replace microwell plates as the industry standard of the future.

"We view our Singapore operation as critical to our long-term success," said Fluidigm CEO Gajus Worthington. "This group has proven its mettle with production of our first product, TOPAZ® screening chips. Now, we are poised for high-volume, low-cost manufacturing to meet the demand in a much larger market." Manufacturing engineers at corporate headquarters in South San Francisco collaborated with the Singapore team to bring the facility up to speed. The off-shore strategy takes advantage of Singapore's high-quality talent, which is a legacy of its semiconductor industry.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy